OREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE. OPERATING PROCEDURES Updated: March 2018

Size: px
Start display at page:

Download "OREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE. OPERATING PROCEDURES Updated: March 2018"

Transcription

1 OREGON HEALTH AUTHORITY DRUG USE REVIEW/PHARMACY AND THERAPEUTICS COMMITTEE OPERATING PROCEDURES Updated: March 2018 MISSION: To encourage safe, effective, and innovative drug policies that promote high value medications for patients served by the Oregon Health Plan (OHP) and other health care programs under the Oregon Health Authority (OHA) by evidence-based committee review of drug use research, clinical guidance and education. DUTIES: As defined by Oregon Revised Statutes (Chapter 414) the Pharmacy and Therapeutics (P&T) Committee was established to perform functions previously fulfilled by the Drug Use Review Board and Health Resources Commission. Responsibilities of the P&T committee include: 1. Evaluate evidence-based reviews of prescription drug classes or individual drugs to assist in making recommendations to the OHA for drugs to be included on the preferred drug list (PDL). a. The P&T Committee may direct a Subcommittee to prepare these reviews. 2. Advise the OHA on administration of Federally mandated Medicaid retrospective and prospective drug use review (DUR) programs which includes recommending utilization controls, prior authorization requirements, quantity limits and other conditions for coverage. 3. Recommendations will be based on evaluation of the available evidence regarding safety, efficacy and value of prescription drugs, as well as the ability of Oregonians to access prescriptions that are appropriate for their clinical conditions. 4. Publish and distribute educational information to prescribers and pharmacists regarding the committee activities and the drug use review programs. 5. Collaborate with the Health Evidence Review Commission (HERC) on topics involving prescription drugs that require further considerations under the purview of the HERC. 6. Guide and approve meeting agendas. 7. Periodically review and update operating procedures and evidence grading methods as needed. AD-HOC EXPERT INVOLVEMENT: 1. A medical expert may be chosen and appointed by the Director of the OHA to provide clinical or treatment expertise in response to a request by the P&T Committee or an interested outside party. The ad-hoc expert must be a licensed physician in Oregon who manages patients who would potentially receive the particular drug(s).

2 2. If an interested outside party requests that an ad-hoc expert be appointed for a particular drug, this request must be made 90 days before the scheduled Committee meeting to ensure adequate time for the appointment process. 3. The medical experts shall have full voting rights with respect to the PDL drugs for which they have been selected and appointed including all utilization controls, prior authorization requirements, review of confidential pricing information or other conditions for the inclusion of a drug on the PDL. The medical experts may participate but may not vote in any other activities of the committee. 4. P&T staff also may engage relevant health care professionals with clinical specialty to serve as expert reviewers, in addition to the ad-hoc experts, if needed. CONDUCT OF MEETINGS: 1. All meetings and notice of meetings will be held in compliance with the Oregon Public Meetings Law. 2. The P&T Committee will elect a Chairperson and Vice Chairperson to conduct the meetings. Elections shall be held the first meeting of the calendar year. 3. Quorum consists of 6 permanent members of the P&T Committee. Quorum is required for any official vote or action to take place throughout a meeting. 4. All official actions must be taken by a public vote. Any recommendation from the Committee requires an affirmative vote of a majority of the Committee members. 5. The committee shall meet in executive session for purposes of reviewing the prescribing or dispensing practices of individual prescribers or pharmacists; reviewing profiles of individual patients; and reviewing confidential drug pricing information to inform the recommendations regarding inclusion of drugs on the Practitioner-Managed Prescription Drug Plan (PMPDP) or any preferred drug lists adopted by the OHA. 6. Meetings will be held at least quarterly but the Committee may be asked to convene up to monthly by the call of the OHA Director or a majority of the members of the Committee. DUR programs will be the focus of the meeting quarterly. 7. Agenda items for which there are no recommended changes based on the clinical evidence may be included in a consent agenda. a. Items listed under the consent agenda will be approved by a single motion without separate discussion. If separate discussion is desired, that item will be removed from the consent agenda and placed on the regular business agenda. b. Consent agenda items may include (but are not limited to) meeting minutes, drug class literature scans, and abbreviated drug reviews for unfunded conditions. CONFLICT OF INTEREST POLICY: The P&T Committee will function in a way that ensures the objectivity and credibility of its recommendations. 1. All potential initial committee members, staff members and consultants, future applicants, expert or peer reviewers, and ad-hoc medical experts selected for individual P&T Committee meetings are subject to the Conflict of Interest disclosure requirements in ORS Chapter 244 and are required to submit a completed disclosure form as part of the appointment process which must be updated promptly with any changes in status.

3 2. Staff members are required to have no financial conflicts related to any pharmaceutical industry business for duration of work on P&T projects. 3. All disclosed conflicts will be considered before an offer of appointment is made. 4. If any material conflict of interest is not disclosed by a member of the P&T Committee on his or her application or prior to participation in consideration of an affected drug or drug class or other action of the Committee, that person will not be able to participate in voting decisions of the affected drug or drug class and may be subject to dismissal. Circumstances in which conflicts of interest not fully disclosed for peer reviewers, ad-hoc experts, or persons providing public comment will be addressed on a case by case basis. 5. Any person providing public testimony will also be required to disclose all conflicts of interest including, but not limited to, industry funded research prior to any testimony pertaining to issues before the P&T Committee. This includes any relationships or activities which could be perceived to have influenced, or that would give the appearance of potentially influencing testimony. PUBLIC COMMENT: 1. The P&T Committee meetings will be open to the public 2. The P&T Committee shall provide appropriate opportunity for public testimony at each meeting a. Testimony can be submitted in writing or provided in-person b. Maximum of 3 minutes per speaker/institution per agenda item i. Information that is most helpful to the Committee is evidence-based and comparative research, limited to new information not already being reviewed by the Committee. ii. Oral presentation of information from FDA-approved labeling (i.e., Prescribing Information or package insert ) is not helpful to the Committee. c. Written testimony can be submitted by interested parties for the P&T Committee to consider on agenda items. Written testimony that includes clinical information should be submitted for evaluation by staff at least 2 weeks prior to the scheduled meeting through the public comment link found on the P&T Committee website: ( earch+and+management). d. Written documents provided during scheduled public testimony time of P&T Committee meetings will be limited to 2 pages of new information that was not included in previous reviews. Prescribing Information is not considered new information; only clinically relevant changes made to Prescribing Information should be submitted. REVIEW STANDARDS AND PREFERRED SOURCES OF EVIDENCE 1. The P&T Committee and department staff will evaluate drug and drug class reviews based on sound evidence-based research and processes widely accepted by the medical profession. These evidence summaries inform the recommendations for management of the PDL and clinical prior authorization criteria. These methods support the principles of evidence-based medicine and will continue to evolve to

4 best fit the needs of the Committee and stay current with best practices. For detailed description of review standards, preferred sources of evidence, and evidence grading methods, see Quality Assessment Tool and Evidence Grading Methods. 2. Final documents as outlined in Chapter 414 of the Oregon Revised Statutes shall be made publicly available at least 30 days prior to review by the P&T Committee. Written public comments may be submitted and considered during the draft comment period prior to posting of final documents. Posted documents will include the agenda for the meeting, a list of drug classes to be considered, and background materials and supporting documentation which have been provided to committee members with respect to drugs and drug classes that are before the committee for review. DRUG AND DRUG CLASS REVIEWS: 1. Drug Class Reviews and New Drug Evaluations: a. The P&T Committee will review drugs and drug classes that have not been previously reviewed for PDL inclusion or for clinical PA criteria and will be prioritized based on: i. Potential benefit or risk ii. Use or potential use in covered population iii. Potential for inappropriate use iv. Alternatives available v. OHP coverage based on opportunities for cost savings, to ensure medically appropriate drug use, or address potential safety risks. b. The P&T Committee will make a reasonable effort to perform a timely review of new FDAapproved drug products following their market release, when they are a new molecular entity and are candidates for coverage under the pharmacy benefit. i. Until new drugs are reviewed by the P&T Committee, drugs meeting the following criteria will be reviewed to ensure they are used appropriately for an FDA-approved or compendia-supported indication, with FDA-approved dosing, and that the indication is funded by the OHP: a. A new drug in a drug class with clinical prior authorization criteria. b. A new drug used for a non-funded condition on the HERC Prioritized List of Health Services. c. A new drug not in a PDL class with existing PA criteria identified by the reviewing pharmacist during the weekly claim processing drug file load costing more than $5,000 per claim or $5,000 per month. c. Line Extension and Combination Product Policy i. Line extensions include new strengths or new formulations of an existing drug. 1. When a new strength or formulation becomes available for a drug previously reviewed for the PDL and has PA criteria and the new product does not significantly differ from the existing drug based on clinical evaluation, the same utilization restrictions as the existing drug will apply until the new strength or formulation is presented to the P&T Committee for review. 2. If a new strength or formulation becomes available for an existing preferred drug and the new product significantly differs from the existing medication in clinical uses or cost, the drug will not be preferred until the drug is reviewed by the P&T Committee. ii. When a new combination product becomes available that is a formulation of one or more drugs that have been reviewed for the PDL, the product will be designated a nonpreferred drug until the P&T Committee reviews the combination product.

5 iii. When a product becomes available that is a biosimilar for one or more drugs that have been reviewed for the PDL, where applicable, the product will be designated a nonpreferred drug until the P&T Committee reviews the product. A complete list of biological products and biosimilar products can be accessed at the FDA s Purple Book website. 2. Drug Class Literature Scans and Abbreviated Drug Reviews: a. Literature of drug classes that have previously been reviewed for the PDL will be scanned and evaluated as needed to assess the need to update drug policies based on clinically relevant information and significant changes in costs published since the last review. b. Abbreviated drug reviews will evaluate drugs for unfunded conditions. Evidence supporting these reports is derived primarily from information in the product labeling. HIGH COST MARGINAL BENEFIT THERAPIES POLICY 1. The goal of this policy is to collaborate with and assist the HERC to evaluate available evidence with a transparent process to encourage safe and financially sustainable policies that maximize access to high value medications for patients served by the OHP. 2. The P&T Committee evaluates drugs for evidence of clinical effectiveness and safety as defined by the P&T Committee Operating Procedures for PDL decision-making. 3. After the clinical review, cost is considered in the executive session. After the executive session, recommendations to be made to the OHA are made with a public vote. 4. The P&T Committee may elect to recommend the HERC consider adding drugs that exhibit one or more of the following characteristics to the Prioritized List of Health Services: a. Marginal clinical benefit b. No clinically important benefit c. Harms that outweigh benefits d. Very high cost in which the benefit does not justify the cost e. Significantly greater cost compared to alternate therapies when both have similar benefit f. Significant budget impact that could affect the overall Prioritized List funding level

Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT)

Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT) 6 October 2016 EMA/CVMP/ADVENT/630299/2014 Rev.2 Committee for Medicinal Products for Veterinary Use (CVMP) Mandate, objectives and rules of procedure for the CVMP Ad Hoc Expert Group on Veterinary Novel

More information

Policy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)

Policy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to

More information

DIAMOND OFFSHORE DRILLING, INC. Corporate Governance Guidelines

DIAMOND OFFSHORE DRILLING, INC. Corporate Governance Guidelines Revised 19 October 2009 DIAMOND OFFSHORE DRILLING, INC. Corporate Governance Guidelines Introduction The following Corporate Governance Guidelines ( Guidelines ) have been adopted by the Board of Directors

More information

II. Funding of Guideline Development Direct funding of evidence-based guideline production by medical and pharmaceutical industry is prohibited.

II. Funding of Guideline Development Direct funding of evidence-based guideline production by medical and pharmaceutical industry is prohibited. EVIDENCE-BASED CLINICAL PRACTICE GUIDELINES Approved: Board of Directors 10/4/97 Revised: Board of Directors 12/10/00 Revised: Board of Directors 11/23/02 Revised: Board of Directors 2/19/05 Revised: Board

More information

GLENVEAGH PROPERTIES PLC REMUNERATION AND NOMINATION COMMITTEE TERMS OF REFERENCE

GLENVEAGH PROPERTIES PLC REMUNERATION AND NOMINATION COMMITTEE TERMS OF REFERENCE GLENVEAGH PROPERTIES PLC REMUNERATION AND NOMINATION COMMITTEE TERMS OF REFERENCE Contents Page 1. Purpose and Role 1 2. Membership and attendees 1 3. Secretary and administration 2 4. Quorum 2 5. Frequency

More information

Board Charter Z Energy Limited

Board Charter Z Energy Limited Board Charter Z Energy Limited Z Energy Limited ( Z Energy ) is committed to the highest standards of corporate governance. This Board Charter ( Charter ) is the foundation document which sets out the

More information

Off-Label Use of FDA-Approved Drugs and Biologicals

Off-Label Use of FDA-Approved Drugs and Biologicals Off-Label Use of FDA-Approved Drugs and Biologicals Last Review Date: January 12, 2018 Number: MG.MM.AD.06cC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician

More information

Protocol for Developing Multi-Stakeholder Group Terms of Reference and Internal Governance Rules and Procedures

Protocol for Developing Multi-Stakeholder Group Terms of Reference and Internal Governance Rules and Procedures Protocol for Developing Multi-Stakeholder Group Terms of Reference and Internal Governance Rules and Procedures February 2015 Protocol for Developing Multi-Stakeholder Group Terms of Reference and Internal

More information

CHARTER OF THE BOARD OF DIRECTORS

CHARTER OF THE BOARD OF DIRECTORS SUN LIFE FINANCIAL INC. CHARTER OF THE BOARD OF DIRECTORS This Charter sets out: 1. The duties and responsibilities of the Board of Directors (the Board ); 2. The position description for Directors; 3.

More information

Charter of the Supervisory Board NN Group N.V.

Charter of the Supervisory Board NN Group N.V. Charter of the Supervisory Board NN Group N.V. 1. RESPONSIBILITIES OF THE SUPERVISORY BOARD 1.1 The Supervisory Board supervises the management of the Executive Board and the general course of affairs

More information

Transitioning to Express Scripts

Transitioning to Express Scripts Transitioning to Express Scripts Welcome to Express Scripts. We re pleased to announce that, beginning January 1, 2017 the Michigan Tech prescription benefit will be managed by Express Scripts. Express

More information

Availability of Masked and De-identified Non-Summary Safety and Efficacy Data; Request for

Availability of Masked and De-identified Non-Summary Safety and Efficacy Data; Request for This document is scheduled to be published in the Federal Register on 06/04/2013 and available online at http://federalregister.gov/a/2013-13083, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network

Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network 1.0 Leadership and Decision-Making When reading this document it is important to note that there are several categories

More information

Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM

Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM 1. Compliance with Law All colleagues, officers and directors of the Company shall respect and comply with all applicable federal, state, local and foreign

More information

COLLEGE OF PHYSICIANS AND SURGEONS OF ONTARIO GOVERNANCE PROCESS MANUAL

COLLEGE OF PHYSICIANS AND SURGEONS OF ONTARIO GOVERNANCE PROCESS MANUAL COLLEGE OF PHYSICIANS AND SURGEONS OF ONTARIO GOVERNANCE PROCESS MANUAL December 2016 Table of Contents Governance Roles and Responsibilities Table of Contents OVERVIEW OF GOVERNANCE... 3 GOVERNANCE ROLES

More information

SHAW COMMUNICATIONS INC. BOARD OF DIRECTORS MANDATE

SHAW COMMUNICATIONS INC. BOARD OF DIRECTORS MANDATE SHAW COMMUNICATIONS INC. BOARD OF DIRECTORS MANDATE This Mandate of the Board of Directors (the Board ) of Shaw Communications Inc. (the Corporation ) was adopted October 23, 2014. I. Mandate The Board

More information

Charter of the Remuneration Committee of the Board of Directors of Novo Nordisk A/S

Charter of the Remuneration Committee of the Board of Directors of Novo Nordisk A/S Charter of the Remuneration Committee of the Board of Directors of Novo Nordisk A/S CVR no. 24 25 67 90 CHARTER OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS OF NOVO NORDISK A/S 6 DECEMBER 2017

More information

DineEquity, Inc. Corporate Governance Guidelines

DineEquity, Inc. Corporate Governance Guidelines DineEquity, Inc. Corporate Governance Guidelines The following Corporate Governance Guidelines have been adopted by the Board of Directors (the Board ) of DineEquity, Inc. (the Corporation ) to assist

More information

Dah Sing Banking Group Limited Nomination and Remuneration Committee - Terms of Reference

Dah Sing Banking Group Limited Nomination and Remuneration Committee - Terms of Reference Dah Sing Banking Group Limited Nomination and Remuneration Committee - Terms of Reference 1. Constitution 1.1 The Nomination and Remuneration Committee (the "Committee or NRC") is established by the Board

More information

Swiss Multiple Sclerosis Society Rules of Procedure for the Scientific Advisory Board

Swiss Multiple Sclerosis Society Rules of Procedure for the Scientific Advisory Board Swiss Multiple Sclerosis Society Rules of Procedure for the Scientific Advisory Board Based on Art. 8 of the Statutes, the following Rules of Procedure for the Scientific Advisory Board (SAB) are adopted:

More information

GOLD FIELDS LIMITED. ( GFI or the Company ) BOARD CHARTER. (Approved by the Board of Directors on 16 August 2016)

GOLD FIELDS LIMITED. ( GFI or the Company ) BOARD CHARTER. (Approved by the Board of Directors on 16 August 2016) 1 GOLD FIELDS LIMITED ( GFI or the Company ) BOARD CHARTER (Approved by the Board of Directors on 16 August 2016) 2 1. INTRODUCTION The Board Charter is subject to the provisions of the South African Companies

More information

PRUDENTIAL FINANCIAL, INC. CORPORATE GOVERNANCE PRINCIPLES AND PRACTICES

PRUDENTIAL FINANCIAL, INC. CORPORATE GOVERNANCE PRINCIPLES AND PRACTICES PRUDENTIAL FINANCIAL, INC. CORPORATE GOVERNANCE PRINCIPLES AND PRACTICES A. THE ROLE OF THE BOARD OF DIRECTORS 1. Direct the Affairs of the Corporation for the Benefit of Shareholders The Prudential board

More information

The primary purposes of the Corporate Governance Committee shall be to shape the corporate governance of the Company, and by doing so shall:

The primary purposes of the Corporate Governance Committee shall be to shape the corporate governance of the Company, and by doing so shall: CONSTELLATION BRANDS, INC. BOARD OF DIRECTORS CORPORATE GOVERNANCE COMMITTEE CHARTER Composition and Member Qualifications The Corporate Governance Committee of the Board of Directors shall be composed

More information

POLARIS INDUSTRIES INC.

POLARIS INDUSTRIES INC. POLARIS INDUSTRIES INC. Board of Directors Corporate Governance Guidelines Table of Contents BOARD ROLES AND RESPONSIBILITIES... 1 Role of the Board... 1 Board Responsibilities... 1 Expectations of Individual

More information

CORPORATE POLICIES AND PROCEDURES. GIFTS NO.: (Formerly ADM X 260)

CORPORATE POLICIES AND PROCEDURES. GIFTS NO.: (Formerly ADM X 260) CORPORATE POLICIES AND PROCEDURES GIFTS NO.: 00365 (Formerly ADM X 260) ISSUED BY: V.P. Human Resources DATE OF APPROVAL: 2008/10/08 APPROVED BY: Senior Management LAST REVIEW/REVISION DATE: Committee

More information

SEMPRA ENERGY. Corporate Governance Guidelines. As adopted by the Board of Directors of Sempra Energy and amended through December 15, 2017

SEMPRA ENERGY. Corporate Governance Guidelines. As adopted by the Board of Directors of Sempra Energy and amended through December 15, 2017 SEMPRA ENERGY Corporate Governance Guidelines As adopted by the Board of Directors of Sempra Energy and amended through December 15, 2017 I Role of the Board and Management 1.1 Board Oversight Sempra Energy

More information

provide leadership to the Company by practising ethical and sustainable decision making in the best interest of the Company and shareholders;

provide leadership to the Company by practising ethical and sustainable decision making in the best interest of the Company and shareholders; GUYANA GOLDFIELDS INC. BOARD OF DIRECTORS MANDATE PURPOSE 1. The Board of Directors (the Board ) is responsible for the stewardship of the business and affairs of Guyana Goldfields Inc. (the Company ).

More information

CORPORATE GOVERNANCE GUIDELINES

CORPORATE GOVERNANCE GUIDELINES CORPORATE GOVERNANCE GUIDELINES OF Ed. Nov.2016 TABLE OF CONTENTS A. DIRECTOR RESPONSIBILITIES 4 B. DIRECTOR QUALIFICATION STANDARDS 4 (1) Board Membership Criteria 4 (a) Independence 4 (b) Limits on Number

More information

FRONTERA ENERGY CORPORATION CORPORATE GOVERNANCE POLICY

FRONTERA ENERGY CORPORATION CORPORATE GOVERNANCE POLICY FRONTERA ENERGY CORPORATION CORPORATE GOVERNANCE POLICY Frontera Energy Corporation, including all of its subsidiaries (as such term is defined in the Code of Business Conduct and Ethics) and Fundación

More information

AUDIT COMMITTEE CHARTER

AUDIT COMMITTEE CHARTER AUDIT COMMITTEE CHARTER CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS (As amended and restated on November 30, 2016.) The responsibilities of the Board of Directors of The Walt Disney Company

More information

CANADIAN NATURAL RESOURCES LIMITED (the Corporation ) BOARD OF DIRECTORS CORPORATE GOVERNANCE GUIDELINES

CANADIAN NATURAL RESOURCES LIMITED (the Corporation ) BOARD OF DIRECTORS CORPORATE GOVERNANCE GUIDELINES CANADIAN NATURAL RESOURCES LIMITED (the Corporation ) BOARD OF DIRECTORS CORPORATE GOVERNANCE GUIDELINES The Board of Directors (the Board ) of the Corporation has adopted the following Corporate Governance

More information

CISCO SYSTEMS, INC. CORPORATE GOVERNANCE POLICIES

CISCO SYSTEMS, INC. CORPORATE GOVERNANCE POLICIES I. BOARD COMPOSITION CISCO SYSTEMS, INC. CORPORATE GOVERNANCE POLICIES A. Size of the Board. The Company s Bylaws provide that the Board will be not less than 8 nor more than 15 directors. The Board will

More information

Chin Koerner Executive Director US Regulatory and Development Policy

Chin Koerner Executive Director US Regulatory and Development Policy Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com

More information

JACOBS ENGINEERING GROUP INC. CORPORATE GOVERNANCE GUIDELINES

JACOBS ENGINEERING GROUP INC. CORPORATE GOVERNANCE GUIDELINES JACOBS ENGINEERING GROUP INC. CORPORATE GOVERNANCE GUIDELINES Role of the Board of Directors The primary responsibilities of the Board of Directors of the Company (the Board ) are oversight, counseling

More information

THE RYLAND GROUP, INC.

THE RYLAND GROUP, INC. THE RYLAND GROUP, INC. GUIDELINES ON SIGNIFICANT CORPORATE GOVERNANCE ISSUES As approved by the Board of Directors on February 24, 2015 TABLE OF CONTENTS 1. SIZE AND STRUCTURE OF THE BOARD... 1 Page 1.1

More information

AUTODESK, INC. CORPORATE GOVERNANCE GUIDELINES. Adopted December 15, Most Recently Amended December 15, 2016

AUTODESK, INC. CORPORATE GOVERNANCE GUIDELINES. Adopted December 15, Most Recently Amended December 15, 2016 AUTODESK, INC. CORPORATE GOVERNANCE GUIDELINES Adopted December 15, 1995 Most Recently Amended December 15, 2016 These guidelines and principles have been adopted by the Board of Directors (the Board )

More information

NEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY

NEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY NEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY MEMORANDUM IN SUPPORT OF AN AMENDMENT TO NEW YORK S PHARMACY LAW

More information

Mandate and objectives for the EMA Working Party on Quality Review of Documents (QRD)

Mandate and objectives for the EMA Working Party on Quality Review of Documents (QRD) 1 July 2014 EMA/403106/2014 Mandate and objectives for the EMA Working Party on Quality Review of Documents 1. General considerations The European Medicines Agency (EMA) created an ad hoc Working Group

More information

Allergan plc Board of Directors Corporate Governance Guidelines

Allergan plc Board of Directors Corporate Governance Guidelines Allergan plc Board of Directors Corporate Governance Guidelines I. Roles and Responsibilities of the Board of Directors The Board of Directors (the Board ), elected by the shareholders, is the ultimate

More information

Standard Operating Procedures Guidelines for Good Clinical Practice

Standard Operating Procedures Guidelines for Good Clinical Practice SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA

More information

CDK GLOBAL, INC. AUDIT COMMITTEE CHARTER Effective January 20, 2016

CDK GLOBAL, INC. AUDIT COMMITTEE CHARTER Effective January 20, 2016 CDK GLOBAL, INC. AUDIT COMMITTEE CHARTER Effective January 20, 2016 I. Purpose The Audit Committee (the Committee ) of the Board of Directors (the Board ) of CDK Global, Inc., a Delaware corporation (the

More information

TG Therapeutics, Inc. Audit Committee Charter

TG Therapeutics, Inc. Audit Committee Charter TG Therapeutics, Inc. Audit Committee Charter I. PURPOSE AND AUTHORITY. The Audit Committee (the "Committee") is a committee appointed by the Board of Directors of TG Therapeutics, Inc. (the "Company").

More information

SUNEDISON, INC. AUDIT COMMITTEE CHARTER (Adopted October 29, 2008)

SUNEDISON, INC. AUDIT COMMITTEE CHARTER (Adopted October 29, 2008) SUNEDISON, INC. AUDIT COMMITTEE CHARTER (Adopted October 29, 2008) I. Purpose The primary purpose of the Audit Committee of the Board of Directors (the Committee ) is to assist the Board of Directors in

More information

Joint Occupational Health and Safety Committee Terms of Reference

Joint Occupational Health and Safety Committee Terms of Reference Joint Occupational Health and Safety Committee Terms of Reference 1. Mandate The Joint Occupational Health and Safety Committee will monitor the University s compliance with the Occupational Health and

More information

FIAT CHRYSLER AUTOMOBILES N.V. AUDIT COMMITTEE CHARTER

FIAT CHRYSLER AUTOMOBILES N.V. AUDIT COMMITTEE CHARTER FIAT CHRYSLER AUTOMOBILES N.V. AUDIT COMMITTEE CHARTER For so long as shares of Fiat Chrysler Automobiles N.V. (the Company ) are listed on the New York Stock Exchange ( NYSE ), the rules of the NYSE and

More information

Cancer Vanguard. Biosimilars Trust Policy Template

Cancer Vanguard. Biosimilars Trust Policy Template Cancer Vanguard Biosimilars Trust Policy Template Aim of this document: The document provides generic guidance and outline for the development of local trust policies in relation to the adoption of biosimilars

More information

German Corporate Governance Code

German Corporate Governance Code (as amended on May 15, 2012) Government Commission German Corporate Governance Code 1 Foreword 1 This German Corporate Governance Code (the "Code") presents essential statutory regulations for the management

More information

American Academy of Orthopaedic Surgeons 2010 Annual Meeting

American Academy of Orthopaedic Surgeons 2010 Annual Meeting American Academy of Orthopaedic Surgeons 2010 Annual Meeting Off-Label Device Use: When Clinical Need Outpaces Regulatory Approval The Legal Parameters of Off-Label Use March 10, 2010 Kathleen McDermott

More information

CORPORATE GOVERNANCE GUIDELINES

CORPORATE GOVERNANCE GUIDELINES CORPORATE GOVERNANCE GUIDELINES The Board of Directors (the Board ) of Gildan Activewear Inc. ( Gildan or the Company ) considers strong and transparent corporate governance practices to be an important

More information

TENET HEALTHCARE CORPORATION CORPORATE GOVERNANCE PRINCIPLES

TENET HEALTHCARE CORPORATION CORPORATE GOVERNANCE PRINCIPLES TENET HEALTHCARE CORPORATION CORPORATE GOVERNANCE PRINCIPLES The Board of Directors of Tenet Healthcare Corporation, acting on the recommendation of its Nominating and Corporate Governance Committee, has

More information

By-Laws for the Supervisory Board of Continental Aktiengesellschaft [Non-binding Convenience Translation]

By-Laws for the Supervisory Board of Continental Aktiengesellschaft [Non-binding Convenience Translation] Version: April 28, 2017 By-Laws for the Supervisory Board of Continental Aktiengesellschaft [Non-binding Convenience Translation] 2 By-Laws for the Supervisory Board of Continental Aktiengesellschaft Section

More information

Appendix B: PDMP Planning Tool

Appendix B: PDMP Planning Tool Appendix B: PDMP Planning Tool Overview In 2014, approximately 19,000 people in the United States died from overdoses of prescription opioids. Prescription drug monitoring programs (PDMPs) are a key resource

More information

Volunteering for Clinical Trials

Volunteering for Clinical Trials Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked

More information

BOARD OF DIRECTORS MANDATE

BOARD OF DIRECTORS MANDATE Page 1 BOARD OF DIRECTORS MANDATE The Board of Directors of SNC-Lavalin Group Inc. (the Corporation ) supervises the management of the Corporation s business and affairs. 1 Composition. The articles of

More information

IMPLEMENTING ACT TO THE POLICY ON DECLARATION OF INTERESTS PROCEDURE FOR IDENTIFYING AND HANDLING POTENTIAL CONFLICTS OF INTEREST

IMPLEMENTING ACT TO THE POLICY ON DECLARATION OF INTERESTS PROCEDURE FOR IDENTIFYING AND HANDLING POTENTIAL CONFLICTS OF INTEREST IMPLEMENTING ACT TO THE POLICY ON DECLARATION OF INTERESTS PROCEDURE FOR IDENTIFYING AND HANDLING POTENTIAL CONFLICTS OF INTEREST INTRODUCTION 1. Article 37 of Regulation (EC) No 178/2002 laying down the

More information

AT&T INC. CORPORATE GOVERNANCE GUIDELINES

AT&T INC. CORPORATE GOVERNANCE GUIDELINES AT&T INC. CORPORATE GOVERNANCE GUIDELINES The Board of Directors of AT&T Inc. ("AT&T") acting on the recommendation of its Corporate Governance and Nominating Committee, has developed and adopted the following

More information

Regulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB

Regulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB Regulatory Pathways Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB johnlaschinger@fda.hhs.gov 1 Disclosures and Disclaimer John C. Laschinger, M.D. I am a full

More information

GROUP 1 AUTOMOTIVE, INC. AUDIT COMMITTEE CHARTER

GROUP 1 AUTOMOTIVE, INC. AUDIT COMMITTEE CHARTER GROUP 1 AUTOMOTIVE, INC. AUDIT COMMITTEE CHARTER The Board of Directors (the Board ) of Group 1 Automotive Inc. (the Company ) has heretofore constituted and established an Audit Committee (the Committee

More information

Regulatory system strengthening

Regulatory system strengthening SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/32 Provisional agenda item 15.6 14 March 2014 Regulatory system strengthening Report by the Secretariat 1. The Executive Board at its 134th session noted an earlier

More information

Juniper Networks, Inc. Corporate Governance Standards. (As amended on October 6, 2009)

Juniper Networks, Inc. Corporate Governance Standards. (As amended on October 6, 2009) Juniper Networks, Inc. Corporate Governance Standards (As amended on October 6, 2009) The Board of Directors (the "Board") of Juniper Networks, Inc. (the "Company") has established the following guidelines

More information

King III Chapter 2 Board Charter. September 2009

King III Chapter 2 Board Charter. September 2009 Chapter 2 Board Charter September 2009 The information contained in this Practice Note is of a general nature and is not intended to address the circumstances of any particular individual or entity. The

More information

Guidance notes and Application Form for Pharmacy Forum NI Guidance Development Pharmacist

Guidance notes and Application Form for Pharmacy Forum NI Guidance Development Pharmacist Guidance notes and Application Form for Pharmacy Forum NI Guidance Development Pharmacist Introduction Pharmacy Forum NI is the professional leadership body for all pharmacists registered to practice in

More information

Too Much of a Good Thing?

Too Much of a Good Thing? Regulatory s Role in Reviewing External Corporate Communications Too Much of a Good Thing? By John Driscoll Every regulatory professional is a reviewer. One could even say that the majority of our work

More information

GOVERNANCE PLAN DRAFT. Operating Guidelines for the Central New York Population Health Improvement Program Advisory Structure

GOVERNANCE PLAN DRAFT. Operating Guidelines for the Central New York Population Health Improvement Program Advisory Structure GOVERNANCE PLAN DRAFT Operating Guidelines for the Central New York Population Health Improvement Program Advisory Structure HealtheConnections 109 South Warren Street State Tower Building, Suite 500 Syracuse

More information

Port of Poole Delivery Board. Terms of Reference

Port of Poole Delivery Board. Terms of Reference Port of Poole Delivery Board Terms of Reference April 2017 1. Purpose 1.1 The mandate for the creation of the Delivery Board came from the 24 th September 2014 meeting of the LEP Board who provided the

More information

BOARD OF DIRECTORS CHARTER

BOARD OF DIRECTORS CHARTER BOARD OF DIRECTORS CHARTER January 1, 2018 CAN_DMS: \106676478\23 BOARD OF DIRECTORS CHARTER Introduction The Board of Directors (the Board ) of Nutrien Ltd. (the Corporation ) is responsible for the stewardship

More information

BOARD GUIDELINES ON SIGNIFICANT CORPORATE GOVERNANCE ISSUES

BOARD GUIDELINES ON SIGNIFICANT CORPORATE GOVERNANCE ISSUES BOARD GUIDELINES ON SIGNIFICANT CORPORATE GOVERNANCE ISSUES Management and the Board of Directors ( Board ) of Nabors Industries Ltd. (the Company ) are committed to conducting business consistent with

More information

HEDIS Measures NCQA s 20 Years of Experience with Measurement

HEDIS Measures NCQA s 20 Years of Experience with Measurement HEDIS Measures NCQA s 20 Years of Experience with Measurement For twenty years, NCQA has refined our process for developing, testing, implementing and maintaining health care quality measures. Researchers,

More information

FDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010

FDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010 FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,

More information

NEWMARK GROUP, INC. AUDIT COMMITTEE CHARTER. (as of December 2017)

NEWMARK GROUP, INC. AUDIT COMMITTEE CHARTER. (as of December 2017) NEWMARK GROUP, INC. AUDIT COMMITTEE CHARTER (as of December 2017) Purpose The Audit Committee of Newmark Group, Inc. (the Company ) is appointed by the Board of Directors of the Company (the Board ) to

More information

W. R. GRACE & CO. CORPORATE GOVERNANCE PRINCIPLES

W. R. GRACE & CO. CORPORATE GOVERNANCE PRINCIPLES W. R. GRACE & CO. CORPORATE GOVERNANCE PRINCIPLES The primary responsibility of the directors of W. R. Grace & Co. is to exercise their business judgment to act in what they reasonably believe to be in

More information

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO) Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of

More information

Charter for the National Clean Plant Network for Hops:

Charter for the National Clean Plant Network for Hops: THE MISSION of the National Clean Plant Network for Hops (NCPN-Hops) is to assist in the production of high quality asexually propagated hop plants free of targeted plant pathogens and pests that cause

More information

The following are matters specifically reserved for the Board:-

The following are matters specifically reserved for the Board:- To establish and review training programme and succession planning to the Board and all candidates appointed to senior management positions are of sufficient calibre; To approve the change of corporate

More information

AMENDED AND RESTATED ON SEMICONDUCTOR CORPORATION CORPORATE GOVERNANCE PRINCIPLES

AMENDED AND RESTATED ON SEMICONDUCTOR CORPORATION CORPORATE GOVERNANCE PRINCIPLES AMENDED AND RESTATED ON SEMICONDUCTOR CORPORATION CORPORATE GOVERNANCE PRINCIPLES (Amended and Restated as of January 1, 2018) The following principles have been approved by the Board of Directors (the

More information

RISK COMMITTEE BYLAW OF THE SUPERVISORY BOARD OF ING BANK ŚLĄSKI S.A.

RISK COMMITTEE BYLAW OF THE SUPERVISORY BOARD OF ING BANK ŚLĄSKI S.A. RISK COMMITTEE BYLAW OF THE SUPERVISORY BOARD OF ING BANK ŚLĄSKI S.A. 1 The Risk Committee of the Supervisory Board of ING Bank Śląski S.A., hereinafter referred to as the Committee, shall perform consultation

More information

IMMUNOGEN, INC. CORPORATE GOVERNANCE GUIDELINES OF THE BOARD OF DIRECTORS

IMMUNOGEN, INC. CORPORATE GOVERNANCE GUIDELINES OF THE BOARD OF DIRECTORS IMMUNOGEN, INC. CORPORATE GOVERNANCE GUIDELINES OF THE BOARD OF DIRECTORS Introduction As part of the corporate governance policies, processes and procedures of ImmunoGen, Inc. ( ImmunoGen or the Company

More information

Canadian Task Force on Preventive Health Care Procedure Manual

Canadian Task Force on Preventive Health Care Procedure Manual Canadian Task Force on Preventive Health Care Procedure Manual October 2011 Page 1 Table of Contents Section 1: Overview of structure and processes... 7 1.1 Function... 7 1.2 Governance... 7 1.3 Overview

More information

The experience of Senegal in conducting ethical research

The experience of Senegal in conducting ethical research The experience of Senegal in conducting ethical research Aissatou Toure Researcher Pasteur Institute Dakar Member of Senegal Health Research National Council Vice Chair of International Bioethic Committee

More information

Governance Principles

Governance Principles Policy and Procedures Maintaining excellence and continuous improvement in the development of DanceSport policies and procedures that facilitate and encourage best practice Table of Contents Governance

More information

CDER s Advisors & Consultants Staff (ACS) Perspective on Preparing for Advisory Committee Meetings. Igor Cerny, Pharm.D. Director, ACS CDER/FDA

CDER s Advisors & Consultants Staff (ACS) Perspective on Preparing for Advisory Committee Meetings. Igor Cerny, Pharm.D. Director, ACS CDER/FDA CDER s Advisors & Consultants Staff (ACS) Perspective on Preparing for Advisory Committee Meetings Igor Cerny, Pharm.D. Director, ACS CDER/FDA Key Points That Will Be Discussed Today s Perspective is CDER

More information

OPTINOSE, INC. CORPORATE GOVERNANCE GUIDELINES

OPTINOSE, INC. CORPORATE GOVERNANCE GUIDELINES OPTINOSE, INC. CORPORATE GOVERNANCE GUIDELINES The Board of Directors (the Board ) of OptiNose, Inc. (the Company ) has adopted these Corporate Governance Guidelines (these Guidelines ) to assist the Board

More information

CANADA (HEALTH CANADA)

CANADA (HEALTH CANADA) 1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers

More information

Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite Connecticut Ave., NW Washington, DC, D

Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite Connecticut Ave., NW Washington, DC, D Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite 1100 1050 Connecticut Ave., NW Washington, DC, 20036 D 202-861-1648 LShea@bakerlaw.com FMT Scenarios Intra-Office Bank Product The Issue The

More information

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE CANCER CENTER SCIENTIFIC REVIEW COMMITTEE The Clinical Scientific Review Committee (SRC) at The Medical College of Wisconsin Cancer Center plays a vital role in protocol review and monitoring to ensure

More information

CITRIX SYSTEMS, INC. CORPORATE GOVERNANCE GUIDELINES. 1. Separation of the Positions of Chairperson and CEO

CITRIX SYSTEMS, INC. CORPORATE GOVERNANCE GUIDELINES. 1. Separation of the Positions of Chairperson and CEO CITRIX SYSTEMS, INC. CORPORATE GOVERNANCE GUIDELINES Set forth below are Citrix Systems, Inc. s corporate governance policies. These guidelines are subject to change from time to time at the direction

More information

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS Purpose of the Audit Committee CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS The Audit Committee (the Committee ) is appointed by the Board of Directors (the Board ) of TechnipFMC plc (the Company

More information

Advance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?

Advance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile? Advance Topics in Pharmacoepidemiology Risk Management 2012 Mid-Year ISPE Meeting Miami, April 21-23, 2012 Ariel E., Arias MD, PhD - Fac. Pharmacy; Université de Montréal - Biologics & Genetic Therapies

More information

Coding Systems Understanding NDC and HCPCS

Coding Systems Understanding NDC and HCPCS Coding Systems Understanding NDC and HCPCS National Drug Code The National Drug Code (NDC) serves as a universal product identifier for prescription medications approved for human consumption. According

More information

Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE

Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE Application form UNIVERSITY OF NOTTINGHAM MEDICAL SCHOOL ETHICS COMMITTEE In completing this form please refer to the attached Notes of Guidance Application for approval of all studies involving Healthy

More information

KOMERCIJALNA BANKA AD SKOPJE CODE OF CORPORATE GOVERNANCE OF KOMERCIJALNA BANKA AD SKOPJE

KOMERCIJALNA BANKA AD SKOPJE CODE OF CORPORATE GOVERNANCE OF KOMERCIJALNA BANKA AD SKOPJE KOMERCIJALNA BANKA AD SKOPJE CODE OF CORPORATE GOVERNANCE OF KOMERCIJALNA BANKA AD SKOPJE April, 2013 1 CONTENT I. GENERAL PROVISIONS II. III. IV. PRINCIPLES OF THE CORPORATE GOVERNANCE.. PROCEDURE OF

More information

Charter of the Audit Committee of the Board of Directors of Novo Nordisk A/S. CVR no

Charter of the Audit Committee of the Board of Directors of Novo Nordisk A/S. CVR no Charter of the Audit Committee of the Board of Directors of Novo Nordisk A/S CVR no. 24 25 67 90 1. Status The Audit Committee is a committee of the Board of Directors established in accordance with Section

More information

People and Safety Committee Charter

People and Safety Committee Charter People and Safety Committee Charter Queensland Rail Queensland Rail ABN 68 598 268 528 Contents 1. Purpose... 1 2. Key Responsibilities....1 3. Membership... 2 4. Meetings... 3 5. Conflicts of Interest...

More information

NATIONAL VISION HOLDINGS, INC. CORPORATE GOVERNANCE GUIDELINES

NATIONAL VISION HOLDINGS, INC. CORPORATE GOVERNANCE GUIDELINES NATIONAL VISION HOLDINGS, INC. CORPORATE GOVERNANCE GUIDELINES INTRODUCTION The Board of Directors (the Board ) of National Vision Holdings, Inc. (the Company ) has adopted these corporate governance guidelines

More information

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products. 1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended

More information

AUDIT COMMITTEE CHARTER

AUDIT COMMITTEE CHARTER AUDIT COMMITTEE CHARTER A. Purpose The purpose of the Audit Committee is to assist the Board of Directors (the Board ) oversight of: the quality and integrity of the Company s financial statements, financial

More information

TERMS OF REFERENCE OF AUDIT & RISK MANAGEMENT COMMITTEE

TERMS OF REFERENCE OF AUDIT & RISK MANAGEMENT COMMITTEE TERMS OF REFERENCE OF AUDIT & RISK MANAGEMENT COMMITTEE 1. Composition a. The Committee shall be appointed by the Board of Directors and shall consist of not less than three (3) members, all of whom shall

More information

Secundum Artem. USP Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations INTRODUCTION BACKGROUND VOLUME 13 NUMBER 4

Secundum Artem. USP Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations INTRODUCTION BACKGROUND VOLUME 13 NUMBER 4 VOLUME 13 NUMBER 4 Secundum Artem Current & Practical Compounding Information for the Pharmacist. USP Chapter Pharmaceutical Compounding - Nonsterile Preparations GOALS AND OBJECTIVES Goal: The goal

More information

BOARD OF DIRECTORS CHARTER

BOARD OF DIRECTORS CHARTER CORPORATE CHARTER Date issued 2005-11-17 Date updated 2016-07-28 Issued and approved by Uni-Select Inc. Board of Directors BOARD OF DIRECTORS CHARTER INTRODUCTION This Charter is intended to identify the

More information

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of Intermediate-size Patient Populations with an Investigational Drug or a REMS-restricted, Approved

More information